Repositioning Candidate Details
| Candidate ID: | R0427 |
| Source ID: | DB04839 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Cyproterone acetate |
| Synonyms: | |
| Molecular Formula: | C24H29ClO4 |
| SMILES: | [H][C@@]12C[C@]1([H])[C@@]1(C)C(=CC2=O)C(Cl)=C[C@@]2([H])[C@]3([H])CC[C@](OC(C)=O)(C(C)=O)[C@@]3(C)CC[C@]12[H] |
| Structure: |
|
| DrugBank Description: | An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females. |
| CAS Number: | 427-51-0 |
| Molecular Weight: | 416.938 |
| DrugBank Indication: | For the palliative treatment of patients with advanced prostatic carcinoma. |
| DrugBank Pharmacology: | Cyproterone is an antiandrogen. It suppresses the actions of testosterone (and its metabolite dihydrotestosterone) on tissues. It acts by blocking androgen receptors which prevents androgens from binding to them and suppresses luteinizing hormone (which in turn reduces testosterone levels). |
| DrugBank MoA: | The direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone. |
| Targets: | Androgen receptor; Prostate-specific antigen |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|